CStone Pharma Replaces Chairman Amid Huge Losses, Irregular Investment
Key Takeaways:
CStone brought four products to market last year, and its losses have surged due to growing R&D and sales spending
Appointment of chairman with close ties to WuXi AppTec reveals a power struggle between shareholders and management
By Molly Wen
Benzinga ·
Benzinga
